Almirall deepens its dermatology dive with a $386M deal

Spanish drugmaker Almirall, moving on from its former focus on respiratory therapies, is beefing up its dermatology pipeline with a buyout of Switzerland's Poli Group.

Bristol-Myers and AbbVie win FDA approval for a 'breakthrough' myeloma treatment

Partners Bristol-Myers Squibb and AbbVie picked up a speedy FDA approval for their cancer immunotherapy, preparing to launch a key cog in each company's oncology pipeline.

Ex-Moderna chief scientist lands at PureTech to seed new biotechs

Joseph Bolen, who quietly left high-profile biotech Moderna Therapeutics earlier this year, has joined startup factory PureTech Health to help the group ferret out promising technologies and launch new companies.

Pfizer turns to GPCR experts at Heptares for a lineup of new drugs

In a deal announced this morning, Pfizer has turned to Heptares to point the way on up to 10 different G protein-coupled receptors, targeting a "superfamily" of cell signaling proteins that plays a major role in modern medicine.

UPDATED: Star fund manager Woodford calls in ex-FBI agent to probe Northwest Bio allegations

Neil Woodford has invested $95 million in Northwest Biotherapeutics and its controversial therapeutic cancer vaccine over the past year. And now that he has bought up 28% of the company's stock, he's pushing hard for an independent investigation into allegations of financial impropriety that have been in circulation since before he took his first big stake in the biotech.

UPDATED: Roche abandons a marquee antibiotics collaboration with Polyphor

Two years ago, Roche stirred some renewed excitement in the antibiotics field when it signed on to partner with Switzerland's Polyphor on a midstage program, committing up to $560 million on a deal that heralded the pharma giant's return to the field. Today, though, Roche dropped out of the collaboration but promised to maintain its commitment to the antibiotics field.

The most popular FierceBiotech stories of 2015

Why would Martin Shkreli hike an old drug price by 5,000%? Only a 'moron' would ask; Why Axovant's $315M IPO bonanza should scare the hell out of you; and more.

Novo Nordisk taps Ablynx in a $400M deal

Novo Nordisk signed a deal with Ablynx worth up to €377 million ($400 million) to collaborate on so-called nanobodies, antibody fragments designed to split the difference between biologics and small-molecule drugs.

Allergan scoops up some CNS drugs as its $160B Pfizer merger pends

Allergan, seeking to burnish its reputation in R&D, bought into some early-stage treatments for autism and obsessive-compulsive disorder as it prepares to join forces with Pfizer in a massive merger.

Teva wagers up to $410M on Heptares' migraine program

Heptares Therapeutics, acquired by Japan's Sosei earlier this year, signed a deal with Teva Pharmaceutical to co-develop novel migraine treatments, getting in line for as much as $410 million.

BioMarin's hopes in DMD fade after FDA panel pillories its case for approval

BioMarin's odds of winning FDA approval for a Duchenne muscular dystrophy treatment got longer on Tuesday after a group of agency advisers picked apart the company's clinical evidence and raised serious concerns about its safety.

Buzz: Shire is coming back for Baxalta with cash-plus-stock bid

Shire is reportedly preparing a new cash-plus-stock offer for Baxalta. The report comes almost four months after a $30 billion all-stock proposal was dismissed by Baxalta, leaving Shire to ponder how to advance its ambitions to become a rare disease powerhouse.

Lilly's middling lung cancer drug wins FDA approval with a restrictive label

Eli Lilly won FDA approval for a lung cancer treatment that posted only a marginal survival benefit in late-stage clinical trials, gaining clearance to treat a small population of patients with particularly serious disease.

Pharma partner Presage acquires a clinical candidate of its own

Presage Biosciences, a popular partner for oncology drug developers, is wading into clinical development of its own, in-licensing a candidate and using its technology to spotlight potential combination therapies.

Aduro slips after trial patient comes down with a dangerous infection

Aduro BioTech, developing an immunotherapy combination treatment for cancer, watched its share price dip on Tuesday after quietly disclosing that a trial patient developed a serious infection tied to the company's re-engineered bacterial treatment.

What if 21st Century Cures had been around before bapineuzumab blew up?

The so-called 21st Century Cures Act, now making its way through Congress, is designed to speed up the FDA review process for potentially lifesaving medicines by encouraging approvals based on midstage data. But a new case study takes a look at what might have happened if a trio of once-promising Alzheimer's drugs had made it to market before their eventual Phase III failures, painting a grim picture of the bill's potential.

Wilex pitches financing plan to keep R&D going for another year

Wilex has pitched a funding plan to keep its R&D operation going for another 12 months. The aim is to round up enough money to advance an antibody-drug conjugate toward the clinic by supplementing €10 million ($10.6 million) from dievini Hopp BioTech with cash from other sources.

Euro VC veteran gathers €63M for Belgium-based life science fund

Belgian VC shop V-Bio Ventures has raised €63 million ($67 million) to invest in life science startups. The newly formed fund has a remit to back new and emerging biotechs from across Europe, but with strong ties to VIB, the Belgian research institute that spawned Ablynx, is likely to funnel a chunk of its cash into local companies.

AstraZeneca ratchets up tech capabilities of Cambridge R&D site

AstraZeneca has unveiled a clutch of deals to add to the technological capabilities of its new R&D hub in Cambridge, U.K. The agreements will equip the site with robots to carry out high-throughput screening, sound wave tools to dispense compounds and software to share data with external partners.

ProQR tanks after slow enrollment pushes back readout from cystic fibrosis trial

ProQR Therapeutics has pushed back the date on which it expects to deliver data from its cystic fibrosis clinical trials. The delay means it may be late 2016 before ProQR presents data on its challenger to Vertex Pharmaceuticals' grip on the cystic fibrosis market.